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LDL Particle Size by Gradient-Gel Electrophoresis Cannot Be Estimated by LDL-Cholesterol/Apolipoprotein B
Ratios, Daisuke Furuya, Atsuhito Yagihashi, Syunichi Nasu, Teruo Endoh, Tohru Nakamura, Reiko Kaneko, Chinatsu Kamagata, Daisuke Kobayashi, and Naoki Watanabe * (Department of Clinical Laboratory Medicine, Sapporo Medical University School of Medicine, South-1, West-16, Chuo-Ku, Sapporo 060-8543, Japan; * author for correspondence: fax 81-11-622-7502, e-mail watanabn@sapmed.ac.jp) LDL particles have been shown to be heterogeneous in size, density, and composition. Heterogeneity of LDL particles with respect to size has been demonstrated by analytic ultracentrifugation (1 ), density-gradient ultracentrifugation, gradient-gel electrophoresis (GGE), high-performance gel-filtration chromatography, dynamic light scattering, and electron microscopy. Among these methods, GGE is the most reliable and widely used, but it has the drawback of being labor-intensive. Recently, the ratio of the LDL-cholesterol (LDL-chol) concentration to the LDL-apolipoprotein B (LDL-apo B) concentration has been used as an alternative index of hyperapobetalipoproteinemia and small dense LDL (2) (3) (4) (5) . We therefore studied the relationship between LDL particle size as measured by GGE and as estimated by the LDL-chol/LDLapo B ratio.
LDL particle size was quantified by the above two methods in samples from healthy controls (n ϭ 49) and from hyperlipemic subjects (n ϭ 81). The hyperlipemic samples in this study were defined according to the criteria of the Japan Atherosclerosis Society [total cholesterol Ն2200 mg/L; triglycerides (TGs) Ն1500 mg/L] (6 ) . GGE was carried out using a 2.4 -15.2% Multilipo nondenaturing gradient gel (Daiichi Pure Chemical). Serum samples (5 L) were electrophoresed on the gel at 25 mA for 2 h. Colloidal gold with standard particle sizes (19.9 and 25.9 nm as confirmed by electron microscopy) was used as a marker for LDL particle size. The colloidal gold particle sizes were also estimated by GGE from a linear calibration curve of the diameter vs the migration dis-tance, with l-lactate dehydrogenase (8.4 nm), catalase (10.4 nm), ferritin (12.2 nm), and thyroglobulin (17.0 nm) as calibrators of known size (7 ) . Bands were analyzed by ) . These analyses were based on homogeneous enzymatic assay (8 ) and turbidimetric immunoassay (9 ) methods, respectively. The LDL-chol and LDL-apo B concentrations as well as the LDL particle sizes as measured by GGE and LDLchol/LDL-apo B ratios are summarized as the mean Ϯ SD in Table 1 . A significant difference in LDL particle size was demonstrated between hyperlipemic and control samples by both GGE and the LDL-chol/LDL-apo B ratio. When LDL particle sizes measured by GGE were plotted against those determined in the same blood samples as LDL-chol/LDL-apo B ratios (Fig. 1) , LDL-chol/LDL-apo B ratios showed a weak negative correlation with LDL particles sizes measured by GGE in control samples (Fig.  1A) and a weak positive correlation in hyperlipemic samples (Fig. 1B) . In control samples, LDL-chol/LDL-apo B ratios were 1.14 -1.39, and LDL particle size measured by GGE was 21.38 -25.41 nm. Among hyperlipemic samples, despite reports that the LDL-chol/LDL-apo B ratio reflects the size of small dense LDL, some samples contained normal-sized LDL particles as determined by GGE but showed low LDL-chol/LDL-apo B ratios. This result reflects the fact that measurement of LDL-chol by the homogeneous enzyme assay is affected by high concentrations of TGs, which leads to underestimation of the LDL-chol concentration (8, 10 ) . LDL size estimated by the LDL-chol/LDL-apo B ratio showed more negative correlation with TG concentrations than that estimated by GGE (r ϭ Ϫ0.68 vs Ϫ0.27). TG concentrations in these two samples were particularly high (8260 and 11 430 mg/L; Fig. 1B, Ⅺ) . In contrast, some samples shown to contain small LDL particles by GGE showed high LDL-chol/LDLapo B ratios. The LDL-chol, LDL-apo B, and TG concentrations ( Fig. 1B, ‚) , respectively, were 1550, 1360, and 1810 mg/L in one sample and 1660, 1320, and 1890 mg/L in the other. When the LDL-chol/LDL-apo B ratio is used to evaluate LDL particle size, the size in these samples will be misreported as normal.
The presence of small, dense LDL increases the risk of atherosclerotic cardiovascular disease beyond that associated with normal LDL (11 ) . Given the importance of LDL particle size determination, it should be performed by GGE rather than rapidly estimated by the LDL-chol/LDLapo B ratio. Transferrin, the principal iron transporter in human serum, is a glycoprotein bearing asparagine-linked polysaccharides (1 ). Because of differences in the glycan structure, several transferrin isoforms can be found in normal serum, the most prominent one containing two biantennary complex-type glycans with a total number of four negatively charged terminal sialic acid residues (2, 3 ) . It has been known for Ͼ20 years that chronically increased consumption of ethanol affects the glycosylation pattern of serum transferrin, producing a higher proportion of transferrin isoforms that lack terminal sialic acid residues and probably other parts of the glycan structure and thus are referred to as carbohydrate-deficient transferrin (CDT) (3) (4) (5) . Originally, CDT was defined as the sum of transferrin isoforms containing two or fewer two sialic acid residues (corresponding to pI values Ն5. 7) , and this definition has likewise been applied to the evaluation of CDT as a sensitive and specific laboratory marker of alcoholism (4, 5 ) . During the last few years, however, commercial kits were launched that measure an operationally defined CDT fraction that in addition to asialo-, monosialo-, and disialo-transferrin also includes at least in part the trisialo-transferrin isoform (6 ) . The inclusion of trisialo-transferrin in the definition of CDT has been claimed to improve the detection of chronic alcohol consumption (7 ) , but the diagnostic significance of the trisialo-transferrin concentration remains unclear (8 ) . Therefore, I reexamined our data from routine determinations of CDT in human serum in search of a quantitative
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